etrasimod
etrasimod: developed by 1 company · 7 clinical trials tracked.
etrasimod evidence translation
What we can confirm
7 tracked trials
What it means
What to watch
Prepared research question
How could etrasimod → ARNA affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 2 study sponsors
Related indications
Development Pipeline (1)
| Company | Phase |
|---|---|
| ARENA PHARMACEUTICALS INC (ARNA) | Phase 2 |
Clinical Trials (7)
Etrasimod as Primary and Secondary Prevention of Pouchitis (ESPIRIT)
Primary endpoint: Proportion of participants with at least 1 episode of acute pouchitis
A PHASE 2 OPEN-LABEL, SINGLE ARM STUDY TO EVALUATE THE EFFICACY, PHARMACOKINETICS, AND SAFETY OF ETRASIMOD IN PEDIATRIC PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
Primary endpoint: Number and percent of enrolled participants with clinical remission based on Modified Mayo Score (MMS) at Week 52
Effectiveness of Etrasimod on Disease Activity and Patient-reported Outcomes in Ulcerative Colitis - EFFECT-UC
Primary endpoint: Proportion of patients with symptomatic remission
An Open-Label, Single-Arm Study to Evaluate the Efficacy, Pharmacokinetics, and Safety of Etrasimod in Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
Primary endpoint: Proportion of Participants Achieving Clinical Remission as Assessed by Modified Mayo Score (MMS) at Week 52
A Randomized, Double Blind, Placebo Controlled, 52 Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects With Moderately Active Ulcerative Colitis
Primary endpoint: Percentage of Participants Achieving Clinical Remission (CR) at Week 52 Using Modified Mayo Score (MMS)
A Multicenter, Randomized, Double-Blind, Parallel-Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to Severely Active Crohn's Disease
Primary endpoint: Percentage of Participants With Endoscopic Response by Simple Endoscopic Score in Crohn's Disease (SES-CD) at Week 14: SSA
An Open-Label Extension Study of Etrasimod in Subjects With Moderately to Severely Active Ulcerative Colitis
Primary endpoint: Number and Severity of Safety Measures
Frequently asked questions
Who is developing etrasimod?
etrasimod is being developed by ARENA PHARMACEUTICALS INC.
How many clinical trials involve etrasimod?
BioSniper tracks 7 clinical trials involving etrasimod.